# CYTALUX™for the Intraoperative Imaging of Prostate Cancer

Source: https://onco.cc/trials/nct06434909/  
OnCo record `nct06434909` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pafolacianine in Prostate cancer, run by Indiana University, completed.

## Summary

CYTALUX™for the Intraoperative Imaging of Prostate Cancer is a phase 2 interventional study registered as NCT06434909 by Indiana University, with 9 participants recorded, started 2024-09-19 and reaching its primary completion in 2025-09-04. Interventions recorded: Cytalux™ (pafolacianine) for fluorescent imaging, Image Guided Surgery. Conditions recorded: Prostate Cancer.

Linked to the drug Pafolacianine because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06434909
- Phase: 2
- Setting: An Investigator Sponsored Study to Investigate the Safety and Efficacy of CYTALUX™ (PAFOLACIANINE) INJECTION for the Intraoperative Imaging of Prostate Cancer
- Sponsor: Indiana University
- Enrolled: 9

## Sources

- ClinicalTrials.gov NCT06434909: https://clinicaltrials.gov/study/NCT06434909

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Pafolacianine](https://onco.cc/drugs/pafolacianine/)

---
JSON: https://onco.cc/api/v1/entities/nct06434909.json